Nature 369, 67–71 (1994)
In this Letter, we reported that the octapeptides Mut1 and 2 (52 FEQNTAQP and A59, respectively), thought to originate from a mutated form of the gap-junction protein connexin 37 with a Cys → Gln mutation in position 3 of the peptide, are shared tumour-specific antigenic epitope(s) of the C57BL/6 Lewis lung carcinoma 3LL clones D122 and Kb39.5, and that they are capable of inducing tumour-specific CTL, tumour immunoprotection, and immunotherapy of established lung metastasis (see also ref. 1). More recent experiments performed in the laboratory of one of us (G.B.) now call into question this finding and conclusions. The experimental details and results will be published elsewhere2; a preprint is available on request.
References
Mandelboim, O. et al. Regression of established murine carcinoma metastases following vaccination with tumor associated antigen peptide. Nature Med. 1, 1179–1183 (1995).
Rosen, D., Brookenthal, K. & Berke, G. An appraisal of the tumor immunoprotective and therapeutic activities of the octapeptides Mut1 and 2 from the mouse Lewis lung carcinoma 3LL. J. Immunol., submitted.
Rights and permissions
About this article
Cite this article
Mandelboim, O., Berke, G., Fridkin, M. et al. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 390, 643 (1997). https://doi.org/10.1038/37678
Published:
Issue Date:
DOI: https://doi.org/10.1038/37678
